Monte Rosa Therapeutics, Inc. Stock Issued During Period, Shares, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Monte Rosa Therapeutics, Inc. stock issued during period, shares, other for the quarter ending 2023-12-31 was 0.00 shares.
- Monte Rosa Therapeutics, Inc. stock issued during period, shares, other for the quarter ending 2023-09-30 was 0.00 shares.
- Monte Rosa Therapeutics, Inc. stock issued during period, shares, other for the quarter ending 2023-06-30 was 0.00 shares.
- Monte Rosa Therapeutics, Inc. stock issued during period, shares, other for the quarter ending 2023-03-31 was 0.00 shares.
- Monte Rosa Therapeutics, Inc. stock issued during period, shares, other for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- Monte Rosa Therapeutics, Inc. stock issued during period, shares, other for fiscal 2022 was 2.48M shares.
| Period end | Stock Issued During Period, Shares, Other 3 month | Stock Issued During Period, Shares, Other 12 month |
|---|---|---|
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 0.00 shares 10-K · filed 2025-03-20 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | |
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-09 | |
| 2022-12-31 | 2.48M shares 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |